| abstract |
The compounds of structural formula I are androgen receptor (AR) modulators of a selective tissue form; they are useful as androgen receptor agonists in bone and / or muscle tissue while antagonizing RA in the prostate of a male patient or in the uterus of a female patient; therefore, these compounds are useful in the treatment of conditions caused by androgen deficiency or that can be improved by the administration of androgens, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage after surgery Bone reconstruction, sarcopenia, frailty, skin aging, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, weakening by HIV, prostate cancer , cancerous cachexia, muscular dystrophies, premature ovarian failure and autoimmune disease, alone or in combination with other active agents. |